BEONE MEDICINES (06160.HK): Grants RSUs Over 52,482 ADSs to 277 Grantees
- The consideration for the grant is nil, and the closing price of the ADSs on the grant date was USD 365.94 per ADS, or approximately HKD 220.97 per ordinary share; each ADS represents 13 ordinary shares of the Company.
- The RSUs vest as to 25% on each anniversary of the last trading day of the month in which the grantee's service relationship commenced over four years, with no performance targets and no clawback mechanism.
NewTimeSpace News: On 6 October 2026, BeOne Medicines Ltd. (stock code: 06160) announced that on 30 September 2026 the compensation committee of the Board granted restricted share units over a total of 52,482 American Depositary Shares to 277 grantees under the terms of the 2016 Stock Option and Incentive Plan. The RSUs correspond to 682,266 shares, representing approximately 0.04% of the Company's total issued shares as at the date of the announcement.
The consideration for the grant is nil, and the closing price of the ADSs on the grant date was USD 365.94 per ADS (approximately HKD 220.97 per ordinary share). The RSUs will vest as to 25% on each anniversary of the last trading day of the month in which the grantee's service relationship commenced over the following four years, subject to the grantee maintaining a continuous service relationship with the Company on the relevant vesting date; for nine grantees who are not senior management, the period between the grant date and the first vesting date is less than 12 months, although the RSUs vest in tranches with a total vesting and holding period exceeding 12 months. The grant is not subject to performance targets and there is no clawback mechanism. Following the grant, 113,721,802 shares, including 23,102,631 shares under the advisor limit, remain available for future grant under the 2016 Stock Option and Incentive Plan.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
